ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-2.69%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$195M
AUM Growth
+$195M
(-21%)
Cap. Flow
-$49.9M
Cap. Flow
% of AUM
-25.63%
Top 10 Holdings %
Top 10 Hldgs %
61.32%
Holding
71
New
16
Increased
14
Reduced
19
Closed
22
Top Buys
| 1 |
Becton Dickinson
BDX
|
$17.3M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$16.7M |
| 3 |
Sabra Healthcare REIT
SBRA
|
$8.39M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$6.75M |
| 5 |
Qiagen
QGEN
|
$6.35M |
Top Sells
| 1 |
Labcorp
LH
|
$10.5M |
| 2 |
Centene
CNC
|
$8.77M |
| 3 |
Merck
MRK
|
$8.13M |
| 4 |
Icon
ICLR
|
$6.85M |
| 5 |
Viking Therapeutics
VKTX
|
$6.26M |
Sector Composition
| 1 | Healthcare | 91.98% |
| 2 | Real Estate | 8.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $24.9M | 12.77% | 255,616 +171,259 | +203% | +$16.7M |
|
|
2
Becton Dickinson
BDX
$55.3B
| $19M | 9.77% | 76,850 +70,089 | +1,037% | +$17.3M |
|
3
Elevance Health
ELV
$71.8B
| $17.2M | 8.82% | 37,326 +11,249 | +43% | +$5.17M |
|
|
4
Sabra Healthcare REIT
SBRA
$4.58B
| $13.4M | 6.89% | 1,165,923 +729,399 | +167% | +$8.39M |
|
|
5
Labcorp
LH
$23.1B
| $10.4M | 5.33% | 45,240 -45,684 | -50% | -$10.5M |
|
|
6
Qiagen
QGEN
$10.1B
| $8.22M | 4.22% | 178,894 +138,145 | +339% | +$6.35M |
|
7
Cigna
CI
$80.3B
| $7.1M | 3.65% | 27,799 -21,879 | -44% | -$5.59M |
|
8
AstraZeneca
AZN
$248B
| $6.75M | 3.47% | 97,257 -44,163 | -31% | -$3.07M |
|
|
9
Teva Pharmaceuticals
TEVA
$21.1B
| $6.75M | 3.47% | +762,264 | New | +$6.75M |
|
|
10
Icon
ICLR
$13.8B
| $5.73M | 2.94% | 26,830 -32,066 | -54% | -$6.85M |
|
11
Moderna
MRNA
$9.37B
| $5.55M | 2.85% | +36,130 | New | +$5.55M |
|
|
12
Merck
MRK
$210B
| $5.27M | 2.71% | 49,573 -76,430 | -61% | -$8.13M |
|
13
Avantor
AVTR
$9.18B
| $4.77M | 2.45% | +225,615 | New | +$4.77M |
|
14
Bio-Rad Laboratories Class A
BIO
$8.06B
| $4.4M | 2.26% | 9,185 +5,292 | +136% | +$2.53M |
|
15
Insmed
INSM
$28.8B
| $3.92M | 2.01% | 230,006 -13,116 | -5% | -$224K |
|
16
Tenet Healthcare
THC
$16.3B
| $3.56M | 1.83% | 59,903 +19,451 | +48% | +$1.16M |
|
17
Cartesian Therapeutics
RNAC
$261M
| $3.01M | 1.55% | 2,166,328 -1,611,290 | -43% | -$2.24M |
|
18
Pfizer
PFE
$141B
| $2.99M | 1.54% | +73,265 | New | +$2.99M |
|
19
Ocular Therapeutix
OCUL
$2.12B
| $2.7M | 1.39% | 512,744 -551,209 | -52% | -$2.9M |
|
20
McKesson
MCK
$85.4B
| $2.6M | 1.34% | +7,312 | New | +$2.6M |
|
21
PTC Therapeutics
PTCT
$3.92B
| $2.58M | 1.32% | 53,247 +35,361 | +198% | +$1.71M |
|
22
DexCom
DXCM
$29.5B
| $2.58M | 1.32% | +22,185 | New | +$2.58M |
|
23
argenx
ARGX
$43.6B
| $2.29M | 1.17% | +6,137 | New | +$2.29M |
|
24
Healthpeak Properties
DOC
$12.5B
| $2.21M | 1.14% | 100,685 +41,107 | +69% | +$903K |
|
25
Dentsply Sirona
XRAY
$2.85B
| $2.2M | 1.13% | 55,992 +33,904 | +153% | +$1.33M |
|